Douglas Lazarus

3.3k total citations · 1 hit paper
38 papers, 2.7k citations indexed

About

Douglas Lazarus is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Douglas Lazarus has authored 38 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 11 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Douglas Lazarus's work include Cancer, Hypoxia, and Metabolism (9 papers), Nanoplatforms for cancer theranostics (7 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Douglas Lazarus is often cited by papers focused on Cancer, Hypoxia, and Metabolism (9 papers), Nanoplatforms for cancer theranostics (7 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Douglas Lazarus collaborates with scholars based in United States, Canada and Spain. Douglas Lazarus's co-authors include Antonia T. Destree, Peter J. Elliott, Julian Adams, Vito J. Palombella, Christine Pien, J I Johnson, Edward A. Sausville, Jochen Maas, Lyle L. Moldawer and S F Lowry and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and The Journal of Immunology.

In The Last Decade

Douglas Lazarus

36 papers receiving 2.6k citations

Hit Papers

Proteasome inhibitors: a novel class of potent and effect... 1999 2026 2008 2017 1999 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Proteasome inhibitors: a novel class of potent and effective antitumor agents.
    1999 1.2k citations Julian Adams, Vito J. Palombella et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Lazarus United States 20 1.5k 774 432 404 399 38 2.7k
Brigitte Bauvois France 30 1.3k 0.9× 1.1k 1.4× 232 0.5× 444 1.1× 619 1.6× 90 3.0k
Paola Izzo Italy 28 1.3k 0.9× 532 0.7× 222 0.5× 186 0.5× 513 1.3× 117 2.6k
Carlos Fernández-Patrón Canada 30 966 0.6× 394 0.5× 332 0.8× 236 0.6× 672 1.7× 63 2.5k
Anthony W. Ashton United States 35 1.8k 1.2× 498 0.6× 158 0.4× 507 1.3× 575 1.4× 87 3.7k
Jiin‐Tsuey Cheng Taiwan 30 1.5k 1.0× 368 0.5× 214 0.5× 291 0.7× 365 0.9× 83 3.0k
Victoria L. Heath United Kingdom 27 1.2k 0.8× 414 0.5× 214 0.5× 901 2.2× 284 0.7× 44 3.2k
Suk Ran Yoon South Korea 34 1.2k 0.8× 617 0.8× 308 0.7× 1.3k 3.1× 354 0.9× 88 2.9k
Takayuki Hoshii Japan 23 2.4k 1.6× 558 0.7× 644 1.5× 572 1.4× 405 1.0× 48 3.6k
H Baumann United States 16 696 0.5× 751 1.0× 206 0.5× 933 2.3× 226 0.6× 27 2.6k
Lidija Klampfer United States 28 1.6k 1.0× 1.2k 1.6× 170 0.4× 683 1.7× 486 1.2× 48 3.2k

Countries citing papers authored by Douglas Lazarus

Since Specialization
Citations

This map shows the geographic impact of Douglas Lazarus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Lazarus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Lazarus more than expected).

Fields of papers citing papers by Douglas Lazarus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Lazarus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Lazarus. The network helps show where Douglas Lazarus may publish in the future.

Co-authorship network of co-authors of Douglas Lazarus

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Lazarus. A scholar is included among the top collaborators of Douglas Lazarus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Lazarus. Douglas Lazarus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ghosh, Subrata, et al.. (2023). Abstract 548: The microRNA-10b targeted therapeutic, TTX-MC138, is effective in preclinical pancreatic adenocarcinoma. Cancer Research. 83(7_Supplement). 548–548. 6 indexed citations
2.
Pham, Elizabeth, Melissa Yin, Christian Peters, et al.. (2016). Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. Cancer Research. 76(15). 4493–4503. 55 indexed citations
3.
Conley, Sarah J., Joseph Burnett, Douglas Lazarus, et al.. (2015). CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Research and Treatment. 150(3). 559–567. 55 indexed citations
4.
5.
Peters, Christian, Douglas Lazarus, Donna M. Brown, et al.. (2015). Abstract B37: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate. Molecular Cancer Therapeutics. 14(12_Supplement_2). B37–B37. 2 indexed citations
6.
Pham, Elizabeth, Michael J. Birrer, Scott Eliasof, et al.. (2014). Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. Clinical Cancer Research. 21(4). 808–818. 77 indexed citations
7.
Lazarus, Douglas, Matthew Labenski, James Wakefield, et al.. (2008). An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis. Inflammation Research. 57(1). 18–27. 11 indexed citations
8.
LePage, Doreen, Douglas Lazarus, Mariano J. Elices, et al.. (2006). Aplidin® combination with chemotherapeutic agents in human melanoma tumors. 66. 504–504. 1 indexed citations
9.
Bernier, Sylvie G., Douglas Lazarus, Matthew Labenski, et al.. (2004). A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proceedings of the National Academy of Sciences. 101(29). 10768–10773. 84 indexed citations
10.
11.
Adams, Julian, Vito J. Palombella, Edward A. Sausville, et al.. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents.. PubMed. 59(11). 2615–22. 1188 indexed citations breakdown →
12.
Solórzano, Carmen C., Riadh Ksontini, Jeffrey H. Pruitt, et al.. (1997). Involvement of 26-kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. The Journal of Immunology. 158(1). 414–419. 74 indexed citations
13.
Lazarus, Douglas, Taku Kambayashi, S F Lowry, & Gideon Strassmann. (1996). The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-26-mediated cancer cachexia. Cancer Letters. 103(1). 71–77. 22 indexed citations
14.
Oldenburg, Hester S. A., et al.. (1995). Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response. Cytokine. 7(6). 510–516. 30 indexed citations
15.
Poll, Tom van der, Douglas Lazarus, C V Keogh, et al.. (1994). Endogenous interleukin-10 protects against death in septic peritonitis in mice. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 95. 18–20. 3 indexed citations
16.
Oldenburg, Hester S. A., Michael A. Rogy, Douglas Lazarus, et al.. (1993). Cachexia and the acute‐phase protein response in inflammation are regulated by interleukin‐6. European Journal of Immunology. 23(8). 1889–1894. 121 indexed citations
17.
Rock, Craig S., Douglas Lazarus, Lisa Staiano‐Coico, et al.. (1991). Impact of exogenous growth hormone on host preservation and tumor cell-cycle distribution in a rat sarcoma model. Journal of Surgical Research. 51(2). 99–105. 16 indexed citations
18.
19.
Lazarus, Douglas & T. Peter Stein. (1988). Invited Comment: Use of Acetate in Total Parenteral Nutrition Solutions. Journal of Parenteral and Enteral Nutrition. 12(6S). 108S–110S. 1 indexed citations
20.
Scanes, Colin G., et al.. (1987). Postnatal changes in circulating concentrations of growth hormone, somatomedin C and thyroid hormones in pigs. Domestic Animal Endocrinology. 4(4). 253–257. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brigitte Bauvois Breakdown of academic impact, for papers by Paola Izzo Breakdown of academic impact, for papers by Carlos Fernández-Patrón Breakdown of academic impact, for papers by Anthony W. Ashton Breakdown of academic impact, for papers by Jiin‐Tsuey Cheng Breakdown of academic impact, for papers by Victoria L. Heath Breakdown of academic impact, for papers by Suk Ran Yoon Breakdown of academic impact, for papers by Takayuki Hoshii Breakdown of academic impact, for papers by H Baumann Breakdown of academic impact, for papers by Lidija Klampfer
Rankless by CCL
2026